Ignite Creation Date:
2024-05-06 @ 5:54 PM
Last Modification Date:
2024-10-26 @ 2:38 PM
Study NCT ID:
NCT05477563
Status:
RECRUITING
Last Update Posted:
2024-05-16
First Post:
2022-07-26
Brief Title:
Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease
Sponsor:
Vertex Pharmaceuticals Incorporated
Organization:
Vertex Pharmaceuticals Incorporated
Organization Data
Organization:
Vertex Pharmaceuticals Incorporated
Class:
INDUSTRY
Study ID:
VX21-CTX001-161
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Vertex Pharmaceuticals Incorporated
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| CRISPR Therapeutics | INDUSTRY |